The International Tennis Integrity Agency (ITIA) today confirms that Daniil Savelev, a 23-year-old tennis player from Russia, has been provisionally suspended under the Tennis Anti-Doping Programme (TADP).
The ITIA sent the player a pre-charge notice of an Anti-Doping Rule Violation on 20 August 2024 under Article 2.1 of the TADP (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid Therapeutic Use Exemption (TUE)).
Savelev, who reached a career-high world doubles ranking of 1486 in August 2022, provided an in-competition sample while competing in an ITF World Tennis Tour M15 event in Hillcrest, South Africa on 3 July 2024.
The sample was split into A and B samples and the subsequent analysis found that the A samples contained meldonium, which is prohibited under the TADP, in the category of Hormone and Metabolic Modulators (section S4 [4.4] of the 2024 World Anti-Doping Agency Prohibited List).
Meldonium is a non-Specified substance, and Savelev did not possess a valid TUE for the substance.
Findings for non-Specified Substances carry a mandatory provisional suspension – in Savelev’s case, this has been in effect from 20 August 2024. Players have the right to appeal the imposition of their provisional suspension before an independent tribunal chair. Savelev elected not to appeal.
While provisionally suspended, Savelev is prohibited from playing in, coaching at, or attending any tennis event authorised or sanctioned by the members of the ITIA (ATP, ITF, WTA, Tennis Australia, Fédération Française de Tennis, Wimbledon and USTA) or any national association.
The ITIA is an independent body established by its tennis members to promote, encourage, enhance, and safeguard the integrity of professional tennis worldwide.
Ends
Published 10 September 2024 15:45
